Every Bridge-covered GLP-1 form, side by side

Weekly pen or daily pill? Semaglutide or tirzepatide? All five covered forms cost the same $50/month under the Bridge — so the real comparison is form, frequency, and trial results. Filter below. Free, no sign-up.

Compare the forms

Trial figures are averages from separate studies with different designs, patients, and lengths — not head-to-head comparisons (except where noted in our full comparison guide). Not promises, and not a recommendation.

Taking Zepbound vials or single-dose pens today? The Bridge covers Zepbound only in the KwikPen — same medication, different packaging. Worth raising with your clinician. Details: covered-drug checker.

How to think about the choice

Since the Bridge flattens all five forms to the same $50 copay, the decision comes down to what you and your clinician weigh: route and frequency (a weekly injection vs. a daily pill — adherence styles differ), trial results (tirzepatide 15 mg and semaglutide 7.2 mg led their separate trials at roughly 21%, with the other forms behind), and side-effect profile (predominantly gastrointestinal across all of them; our full guide covers the differences, including the dysesthesia finding at Wegovy HD's higher dose). None of this is a recommendation — it's the shape of the conversation to have with your doctor.

Frequently asked questions

Is there a pill option?

Two: Foundayo (orforglipron, daily) and Wegovy tablets (oral semaglutide, daily). Both are Bridge-covered at $50/month for people who match the criteria.

Which showed the most weight loss?

In separate trials: Zepbound 15 mg (~21%) and Wegovy HD 7.2 mg (~20.7%) were essentially similar at the top; standard Wegovy 2.4 mg ~15%; Wegovy tablets ~17% (full adherence); Foundayo ~11%.

Why isn't Ozempic or Mounjaro in this comparison?

They're approved for type 2 diabetes, not weight management, so they're outside the Bridge. See the covered-drug checker.

Next step: all five forms share the same criteria — the free screener shows how your answers line up in about 3 minutes and writes your doctor message. No sign-up required.

Sources and review status: Educational only — not medical advice or a recommendation of any medication; your clinician decides what's appropriate. Trial figures from each medication's pivotal obesity trial (STEP-1, STEP UP, OASIS-4, SURMOUNT-1, ATTAIN-1) as summarized in our comparison guide. Content reviewed July 2, 2026. CMS Bridge overview. More free tools: tools hub.